Search Results
Jan 08, 2026, 08:45 ET World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About NeuroSenseNeuroSense Therapeutics, Ltd. is a clinical-stage
More news about: NeuroSense
Jan 08, 2026, 08:38 ET Mercury Bio Launches MB-TIP™--Revolutionizing Immunotherapy with Intracellular Targeting
(Mercury Bio - Targeting Intracellular Pathologies) which harnesses proprietary exosome-based yEV™ technology to deliver large proteins, nanobodies, and RNA into cells at the site of intracellular pathology—enabling medicines to act directly and specifically within the cells where disease originates.
More news about: Mercury Bio Inc.
Jan 08, 2026, 08:30 ET Detecting and Characterizing RNA Drug Candidates to Accelerate Therapeutic Development, Upcoming Webinar Hosted by Xtalks
next-generation sequencing–based approaches map small RNA-target interactions directly across the transcriptome. By directly mapping small RNA-target interactions across the transcriptome, these assays reveal where siRNAs bind, how they influence RNA processing and their downstream impact on gene expression,
More news about: Xtalks
Jan 08, 2026, 08:00 ET Factorial Biotechnologies and Honeycomb Biotechnologies Partner to Deliver High-Throughput, Instrument-Free Single-Cell DNA Sequencing
beyond single-cell RNA sequencing," said Jim Flanigon, CEO of Honeycomb Biotechnologies. "We are thrilled to be working with Factorial and to extend the capabilities of the HIVE."The HIVE platform has gained recognition for its portable, handheld device that enables gentle capture, RNA stabilization,
More news about: Factorial Biotechnologies
Jan 08, 2026, 08:00 ET Klotho Neurosciences to Present at the Biotech Showcase 2026
Alzheimer's disease, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. Klotho is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical
More news about: Klotho Neurosciences, Inc.
Jan 08, 2026, 07:00 ET Replicate Bioscience Awarded Grants to Develop New srRNA Vaccines for HIV and Malaria
of a low-dose, multigenic RNA-based malaria vaccine platform, with the goal of expanding access to effective malaria prevention tools in low- and middle-income countries. A second grant of approximately $3.5 million will support the development of a novel self-replicating RNA-based HIV vaccine candidate
More news about: Replicate Bioscience
Jan 08, 2026, 03:30 ET STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications
N6-methyladenosine (m6A) RNA modifications resulting from METTL3 inhibition. This will be achieved using STORM's first-in-class METTL3 inhibitor, STC-15, which is the first small molecule drug targeting an RNA-modifying enzyme to enter human clinical trials. Post-transcriptional modification of RNA, including
More news about: STORM Therapeutics
Jan 07, 2026, 09:07 ET KilgourMD Announces Exclusive Partnership With N1 Life to Bring Peptide-Based Delivery Technology to Scalp Health
applies these technologies to a diverse R&D program, spanning oncology to dermatology diseases, using payloads ranging from small molecules to RNA/DNA. Their mission is to enhance targeted drug delivery, ensuring that treatments reach their intended cells and tissues effectively, thus opening new
More news about: KilgourMD
Jan 07, 2026, 09:00 ET Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics
which Axolabs will evaluate Codexis' ECO Synthesis Manufacturing Platform. This partnership provides Axolabs access to an innovative, scalable RNA manufacturing solution powered by enzymatic synthesis. The Agreement paves the way for future licensing discussions and potentially broader adoption
More news about: Codexis
Jan 07, 2026, 08:00 ET STRM.BIO Raises $8 Million in Series Seed 2 Financing to Advance Non-Viral Gene Delivery Platform for In Vivo Cell Engineering and Gene Therapy
designed to address the limitations of traditional viral and synthetic delivery systems, unlocking new therapeutic opportunities across gene editing, RNA therapeutics, and immune cell engineering. STRM.BIO is headquartered in Cambridge, Massachusetts.Learn more at
More news about: STRM.BIO
Jan 07, 2026, 08:00 ET SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology
Anderson researchers will tap SOPHiA GENETICS' AI technologies to create bioinformatics pipelines that enable clinicians to rapidly interpret complex RNA-sequencing data to guide diagnosis and treatment for patients with cancer.Donna Hansel, M.D., Ph.D., Division Head of
More news about: SOPHiA GENETICS
Jan 07, 2026, 07:00 ET Xtalks Announces its Life Science Webinar Calendar for January 2026
Bedside: De-Risking Biotherapeutic Administration via CDMO-Led Clinical-Mimic and In-Use Testing StrategiesJan 28 - Detecting and Characterizing RNA Drug Candidates to Accelerate Therapeutic DevelopmentMEDICAL DEVICEJan 21 - Medical Device Validation Solutions for Evolving Industry
More news about: Xtalks
Jan 07, 2026, 07:00 ET Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders
generative molecular design with Unravel's AI-powered BioNAV™ predictive biology platform and Living Molecular Twins™ patient datamine. Using advanced RNA-based network simulations, primary patient data, and predictive AI modeling, Unravel generates novel therapeutic insights and drug targets. This deep
More news about: Evogene
Jan 07, 2026, 03:01 ET BioSpace Names 15 Top Startups to Watch in 2026
well they have been able to adapt and navigate this dynamic landscape."BioSpace considers organizations across all therapeutic areas. RNA therapies, antisense oligonucleotides and CAR Ts are among the products being developed. Winners include Kardigan, Light Horse, Haya and City Therapeutics."It
More news about: BioSpace
Jan 06, 2026, 20:00 ET 晶泰科技賦能國內首個「AI + RNA」小分子創新藥獲批臨床，ReviR溪礫科技實現罕見病首創新藥突破
的臨床進展，再次驗證了晶泰平台 『從算法到臨床』 的快速轉化能力，以及 AI+RNA 的研發路徑在罕見病藥物研發中的巨大潛力。隨著數據與經驗的積累，AI 模型的預測精度和管線產出率將持續提升，有望填補更多臨床空白，為患者、合作夥伴和投資人創造可持續的價值。」ReviR聯合創始人兼董事長李陽博士表示： 「ReviR 聚焦無藥可治的患者群體與未被滿足的臨床需求，致力於利用 AI、立足 RNA 功能，開闢創新治療範式。RTX-117 的臨床獲批，印證了
More news about: 晶泰科技
Jan 06, 2026, 13:27 ET Aperture Therapeutics Announces First-In-Class MMP9 Antisense Oligonucleotide Program for ALS
targets chronic neuroinflammation and neurodegeneration, two core pathological drivers of motor neuron degeneration in ALS and represents a first-in-class RNA-targeting approach to modulate this genetically and mechanistically validated pathway.
More news about: Aperture Therapeutics
Jan 06, 2026, 08:01 ET TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
Jan. 6, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancer, today announced the publication of preclinical research supporting the application of
More news about: TransCode Therapeutics, Inc.
Jan 05, 2026, 06:50 ET Protalix BioTherapeutics Letter to Stockholders
downstream inflammation and fibrosis. PRX–119 has the potential to be a key pipeline asset.Secarna Collaboration: We recently announced an RNA–based collaboration with Secarna Pharmaceuticals utilizing Secarna's AI–powered OligoCreator® platform. This partnership combines our rare
More news about: Protalix BioTherapeutics, Inc.
Jan 02, 2026, 07:00 ET Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States,
More news about: Insmed Incorporated
Dec 30, 2025, 09:00 ET Co-Diagnostics Announces Reverse Stock Split
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Dec 29, 2025, 09:00 ET Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Dec 29, 2025, 06:40 ET Cell and Gene Therapy Market to Exceed US$105B by 2033, Driving Strategic Value Across Healthcare Portfolios | According to DataM Intelligence
with several notable therapy approvals and sustained growth across all stages of clinical development. Currently, more than 4,000 gene, cell, and RNA-based treatments are in research and development globally.The clinical pipeline has expanded significantly across all phases, with Phase
More news about: DataM Intelligence 4 Market Research LLP
Dec 23, 2025, 07:00 ET Senhwa Biosciences Highlights AI-Validated Oncology Platform and Strategic Clinical Collaborations Targeting Next-Generation Immuno-Oncology products at Its 2025 Annual Investor Conference
is a first-in-class small molecule with a differentiated dual mechanism of action that stabilizes DNA G-quadruplex (G4) structures while inhibiting RNA polymerase I (Pol I). This dual activity induces replication stress in tumor cells and activates the innate immune cGAS–STING pathway, effectively converting
More news about: Senhwa Biosciences, Inc.
Dec 22, 2025, 22:56 ET GC Biopharma Secures IND Approval for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea
approved the Investigational New Drug (IND) application for the Phase 1 clinical trial of "GC4006A", mRNA (messenger RNA) vaccine candidate for COVID-19.
More news about: GC Biopharma
Dec 22, 2025, 09:17 ET NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About NeuroSenseNeuroSense Therapeutics, Ltd. is a clinical-stage
More news about: NeuroSense